MedCap AB (publ) (MCAP) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.034x

Based on the latest financial reports, MedCap AB (publ) (MCAP) has a cash flow conversion efficiency ratio of 0.034x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr51.70 Million ≈ $5.56 Million USD) by net assets (Skr1.53 Billion ≈ $164.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MedCap AB (publ) (MCAP) market capitalisation for the company's overall valuation and market capitalisation.

MedCap AB (publ) - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how MedCap AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

MedCap AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of MedCap AB (publ) ranked by their cash flow conversion efficiency. Explore MedCap AB (publ) (MCAP) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Zhejiang JW Precision Machinery Co.Ltd
SHE:300984
0.004x
Hanma Technology Group Co Ltd
SHG:600375
-0.016x
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
N/A
Chongqing Road & Bridge Co Ltd
SHG:600106
0.011x
Anhui Estone Materials Technology Co Ltd
SHG:688733
-0.014x
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
-0.021x
Blue Sail Medical Co Ltd
SHE:002382
-0.007x
Beijing UniStrong Science & Technology Co Ltd
SHE:002383
0.020x

Annual Cash Flow Conversion Efficiency for MedCap AB (publ) (2007–2025)

The table below shows the annual cash flow conversion efficiency of MedCap AB (publ) from 2007 to 2025. View MedCap AB (publ) (MCAP) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr1.46 Billion
≈ $157.00 Million
Skr342.70 Million
≈ $36.88 Million
0.235x -15.94%
2024-12-31 Skr1.29 Billion
≈ $138.63 Million
Skr360.00 Million
≈ $38.74 Million
0.279x +25.89%
2023-12-31 Skr1.03 Billion
≈ $110.53 Million
Skr228.00 Million
≈ $24.54 Million
0.222x +122.94%
2022-12-31 Skr858.70 Million
≈ $92.41 Million
Skr85.50 Million
≈ $9.20 Million
0.100x -40.27%
2021-12-31 Skr697.70 Million
≈ $75.08 Million
Skr116.30 Million
≈ $12.52 Million
0.167x -13.19%
2020-12-31 Skr602.00 Million
≈ $64.78 Million
Skr115.60 Million
≈ $12.44 Million
0.192x -10.50%
2019-12-31 Skr332.80 Million
≈ $35.81 Million
Skr71.40 Million
≈ $7.68 Million
0.215x -35.16%
2018-12-31 Skr273.80 Million
≈ $29.47 Million
Skr90.60 Million
≈ $9.75 Million
0.331x +224.47%
2017-12-31 Skr267.70 Million
≈ $28.81 Million
Skr27.30 Million
≈ $2.94 Million
0.102x -63.41%
2016-12-31 Skr292.29 Million
≈ $31.45 Million
Skr81.46 Million
≈ $8.77 Million
0.279x +675.70%
2015-12-31 Skr308.15 Million
≈ $33.16 Million
Skr-14.92 Million
≈ $-1.61 Million
-0.048x -701.63%
2014-12-31 Skr280.63 Million
≈ $30.20 Million
Skr2.26 Million
≈ $243.00K
0.008x +106.43%
2013-12-31 Skr221.92 Million
≈ $23.88 Million
Skr865.00K
≈ $93.09K
0.004x -98.02%
2012-12-31 Skr195.48 Million
≈ $21.04 Million
Skr38.55 Million
≈ $4.15 Million
0.197x +16.49%
2011-12-31 Skr169.82 Million
≈ $18.28 Million
Skr28.75 Million
≈ $3.09 Million
0.169x -0.54%
2010-12-31 Skr179.99 Million
≈ $19.37 Million
Skr30.64 Million
≈ $3.30 Million
0.170x +67.04%
2009-12-31 Skr169.94 Million
≈ $18.29 Million
Skr17.32 Million
≈ $1.86 Million
0.102x +305.17%
2008-12-31 Skr134.11 Million
≈ $14.43 Million
Skr3.37 Million
≈ $362.99K
0.025x +49.35%
2007-12-31 Skr127.44 Million
≈ $13.71 Million
Skr2.15 Million
≈ $230.94K
0.017x --

About MedCap AB (publ)

ST:MCAP Sweden Medical Devices
Market Cap
$863.10 Million
Skr8.02 Billion SEK
Market Cap Rank
#9610 Global
#153 in Sweden
Share Price
Skr534.00
Change (1 day)
+0.75%
52-Week Range
Skr453.00 - Skr624.00
All Time High
Skr670.00
About

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; an… Read more